Skip to NavigationSkip to content

UCB and Biogen's lupus drug falls short at Phase 2b

Published on 24/10/18 at 11:57am

The partnership of UCB and Biogen announced disappointing news, confirming that its experimental therapy dapirolizumab pegol (DZP) failed to meet its primary endpoint in the treatment of moderately-to-severely active systemic lupus erythematosus (SLE) in adult patients during a Phase 2b trial.

The anti-CD40L pegylated fab was tested in 182 patients with the condition who had not seen results despite receiving standard-of-care treatments like corticosteroids, non-biological immunosuppressants and non-malarials, in groups randomised to receive it in combination with these treatments at one of three doses. However, it failed to demonstrate a dose response after 24 weeks, according to the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA).

Despite this, the pair did note that top-line results demonstrated that the therapy produced “consistent and potentially meaningful improvements for the majority of clinical endpoints” compared with placebo, and that biomarker data showed evidence of proof of biology.

“Biogen and UCB continue to further evaluate these data while assessing potential next steps. The companies expect to present this data at a future scientific forum,” the pair concluded.

Matt Fellows


I want to invite you all people her if you are using windows 10 operating system desktop then you have to know about this how to fix connections to bluetooth audio devices in windows 10 to manage your desktop audio video sounds. Thsi tutorial is free for you, so start getting information. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches